Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMA on health claims

This article was originally published in The Tan Sheet

Executive Summary

American Medical Association "strongly opposes" FDA's decision to "allow a lower standard - the so-called weight of the scientific evidence standard - to be used in deciding whether a health claim can be placed on the labeling of a conventional food product," according to Feb. 21 comments. The "weight of the scientific evidence standard" would allow the use of health claims "that have a reasonable chance of being erroneous" and "actually could confuse consumers" rather than help them to make informed decisions, the medical group contends. Comments respond to FDA's decision to no longer hold health claims for food, supplements to significant scientific agreement standard (1"The Tan Sheet" Dec. 23, 2002, p. 10). AMA also says it is working with Congress to modify DSHEA...

You may also be interested in...



Qualified Health Claims “Reasonable Consumer” Standard Adopted By FDA

FDA will employ a "reasonable consumer" standard, rather than an "ignorant, unthinking and credulous" consumer standard, to determine whether dietary supplement and food labeling is misleading, the agency announced Dec. 18

QUOTED. 9 April 2020. Frans van Houten.

Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.

COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Topics

UsernamePublicRestriction

Register

PS095202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel